Prognostic value of the dual-tracer PET score (NETPET) in neuroendocrine tumors with [225Ac]Ac-DOTATATE therapy
European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8347-8357
DOI: 10.1007/s00259-026-08138-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 17.08.2026. Verfasst von Ya Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, PR China. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Organometallic Compounds, Positron-Emission Tomography, Octreotide. Die Arbeit nennt 24 Literaturangaben. Gefördert von: the Gansu Provincial Science and Technology Major Project, the National Key Research and Development Program (NKRDP) Project, the Scientific Research Project of Southwest Medical University.
Abstract (Originalsprache)
PURPOSE: To investigate the association between baseline NETPET score and prognosis in patients with neuroendocrine tumors (NETs) receiving [225Ac]Ac-DOTATATE therapy. METHODS: This retrospective study included patients with NETs treated with [225Ac]Ac-DOTATATE between November 2021 and March 2025. All patients underwent [18F]F-FDG and [68Ga]Ga-DOTATATE PET within one week before treatment. Up to 10 representative lesions per patient were selected for NETPET scoring. The primary endpoint was progression-free survival (PFS). The relationship between NETPET score and PFS was evaluated using Kaplan-Meier analysis and univariate/multivariate Cox proportional hazards models. RESULTS: Forty-eight patients were enrolled (P1: n = 14, P2-4: n = 22, P5: n = 12). The P1 group achieved significantly better PFS than the P2-4 and P5 groups (2-year PFS rates: 0.83 vs. 0.32 vs. 0.10; log-rank P 0.05). CONCLUSION: The NETPET score was independently associated with progression-free survival and may serve as a potential imaging biomarker for pretreatment risk stratification in NET patients receiving [225Ac]Ac-DOTATATE therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, PR China.
- Department of Nuclear Medicine, Laboratory of Sichuan Province Institute of Nuclear Medicine, Affiliated Hospital of Southwest Medical University Nuclear Medicine and Theranostics Key, Southwest Medical University , No…
- Department of Nuclear Medicine, Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Institute of Nuclear Medicine, Southwest Medical Univer…
- Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, PR China. 315699969@qq.com.
- Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, PR China. zhangyu309@126.com.
- Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, PR China. chenyue5523@126.com.
Förderung
- the Gansu Provincial Science and Technology Major Project
- the National Key Research and Development Program (NKRDP) Project
- the Scientific Research Project of Southwest Medical University
Zitieren
APA
Liu, Y., Xu, T., Yang, H., Huang, Z., Ding, H., Zhang, Y., & Chen, Y. (2026). Prognostic value of the dual-tracer PET score (NETPET) in neuroendocrine tumors with [225Ac]Ac-DOTATATE therapy. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8347-8357. https://doi.org/10.1007/s00259-026-08138-0
Vancouver
Liu Y, Xu T, Yang H, Huang Z, Ding H, Zhang Y, et al. Prognostic value of the dual-tracer PET score (NETPET) in neuroendocrine tumors with [225Ac]Ac-DOTATATE therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8347-8357. doi:10.1007/s00259-026-08138-0
BibTeX
@article{Liu2026,
author = {Liu, Ya and Xu, Tingting and Yang, Hongyu and Huang, Zhanwen and Ding, Haoyuan and Zhang, Yu and Chen, Yue},
title = {Prognostic value of the dual-tracer PET score (NETPET) in neuroendocrine tumors with [225Ac]Ac-DOTATATE therapy},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {13},
pages = {8347--8357},
doi = {10.1007/s00259-026-08138-0}
}
EUVIMED